Munck, AnneAnneMunckBerger, Daria OlenaDaria OlenaBerger0000-0002-9188-5064Southern, Kevin WKevin WSouthernCarducci, CarlaCarlaCarduccide Winter-de Groot, Karin MKarin Mde Winter-de GrootGartner, SilviaSilviaGartnerKashirskaya, NataliyaNataliyaKashirskayaLinnane, BarryBarryLinnaneProesmans, MarijkeMarijkeProesmansSands, DorotaDorotaSandsSommerburg, OlafOlafSommerburgCastellani, CarloCarloCastellaniBarben, JürgJürgBarben2024-10-112024-10-112023-05https://boris-portal.unibe.ch/handle/20.500.12422/88865BACKGROUND The aim of this study was to record the current status of newborn bloodspot screening (NBS) for CF across Europe and assess performance. METHODS Survey of representatives of NBS for CF programmes across Europe. Performance was assessed through a framework developed in a previous exercise. RESULTS In 2022, we identified 22 national and 34 regional programmes in Europe. Barriers to establishing NBS included cost and political inertia. Performance was assessed from 2019 data reported by 21 national and 21 regional programmes. All programmes employed different protocols, with IRT-DNA the most common strategy. Six national and 11 regional programmes did not use DNA analysis. CONCLUSIONS Integrating DNA analysis into the NBS protocol improves PPV, but at the expense of increased carrier and CFSPID recognition. Some programmes employ strategies to mitigate these outcomes. Programmes should constantly strive to improve performance but large datasets are needed to assess outcomes reliably.enCFSPIDcarriers CFTR gene analysis Cystic fibrosis IRT Newborn bloodspot screening PAP600 - Technology::610 - Medicine & health300 - Social sciences, sociology & anthropology::360 - Social problems & social servicesarticle10.48350/1747403637270010.1016/j.jcf.2022.09.012